Karyopharm Therapeutics reported $301.38M in Debt for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Debt Change
Acceleron Pharma XLRN:US $ 0M 0M
Amgen AMGN:US $ 32782M 97M
AstraZeneca AZN:LN 27495M 7363M
Astrazeneca AZN:US $ 27495M 7363M
Avrobio Inc AVRO:US $ 0 0
Biocryst Pharmaceuticals BCRX:US $ 293.66M 9.32M
Bristol Myers Squibb BMY:US $ 45158M 1124M
Eli Lilly And LLY:US $ 16515.1M 310.6M
Epizyme EPZM:US $ 231.2M 0.69M
GlaxoSmithKline GSK:LN 25483M 736M
Karyopharm Therapeutics KPTI:US $ 301.38M 59.58M
Macrogenics MGNX:US $ 0M 0M
Mirati Therapeutics MRTX:US $ 0M 0M
Nektar Therapeutics NKTR:US $ 0M 0M
Novartis NOVN:VX SF 35769M 2030M
Novartis NVS:US $ 35769M 2030M
Regeneron Pharmaceuticals REGN:US $ 2697.6M 0.9M
Sangamo Biosciences SGMO:US $ 0M 0M
Takeda 4502:JP Y 4405861M 4383708M
Ultragenyx Pharmaceutical RARE:US $ 0M 0M
Xencor XNCR:US $ 0M 0M
YTE INCY:US $ 34.25M 0.22M